Hansoh Pharmaceutical Group is a listed pharmaceutical company based in China with substantial research, development and commercialization activities. The company develops innovative small-molecule and biological medicines and also operates a broader pharmaceutical business. Its official website describes oncology, central nervous system disorders, metabolic conditions, infections and immunology among its therapeutic areas. The corporate site identifies its Hong Kong stock code and offers links to its ongoing research and investor information. This entry focuses on the listed issuer and its enduring drug-development capabilities, rather than reproducing a rapidly changing inventory of products, research assets or financial results.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Hansoh Pharmaceutical Group is a listed pharmaceutical company based in China with substantial research, development and commercialization activities. The company develops innovative small-molecule and biological medicines and also operates a broader pharmaceutical business. Its official website describes oncology, central nervous system disorders, metabolic conditions, infections and immunology among its therapeutic areas. The corporate site identifies its Hong Kong stock code and offers links to its ongoing research and investor information. This entry focuses on the listed issuer and its enduring drug-development capabilities, rather than reproducing a rapidly changing inventory of products, research assets or financial results.
HKEX: 03692
small-molecule pharmaceuticals · biologics
oncology · metabolic disease · immunology · central nervous system · infectious disease
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
HS-20118 / AVR-001 is an oral IL-23R cyclic peptide with disclosed Phase 1 human data. Rights outside Greater China were licensed to Avere.
Business, technology & evidence
2026-05-15Hansoh presents Phase 1 HS-20118 data supporting exploration of weekly oral dosing
2026-07-14Hansoh licenses ex-Greater-China HS-20118 rights to Avere alongside proposed NextCure merger
Hansoh Pharmaceutical Group is a listed pharmaceutical company based in China with substantial research, development and commercialization activities. The company develops innovative small-molecule and biological medicines and also operates a broader pharmaceutical business. Its official website describes oncology, central nervous system disorders, metabolic conditions, infections and immunology among its therapeutic areas. The corporate site identifies its Hong Kong stock code and offers links to its ongoing research and investor information. This entry focuses on the listed issuer and its enduring drug-development capabilities, rather than reproducing a rapidly changing inventory of products, research assets or financial results.
SecuritiesHKEX: 03692
Program / service
Target / indication
Representative stage
Evidence & scope
HS-20118 / AVR-001
IL-23R · Psoriasis / inflammatory and immune diseases
I期结果
Company-disclosed Phase 1 human PK / PD
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Hansoh granted Avere exclusive development, manufacturing, and commercialization rights to HS-20118, also called AVR-001, outside Greater China. The oral cyclic IL-23R antagonist agreement includes $120 million in upfront payments, up to $2.18 billion in milestones, and royalties. Avere also announced a proposed NextCure merger. Conditional milestone value and a signed merger agreement do not represent realized payments or closing.
Hansoh presented two randomized, double-blind, placebo-controlled Phase 1 studies of HS-20118 involving 129 treated participants, including healthy volunteers and 23 patients with psoriasis. The company reported sustained pharmacokinetic and pharmacodynamic activity and early skin-response signals supporting exploration of weekly oral dosing. Small patient cohorts and short treatment duration limit conclusions about comparative efficacy and long-term safety.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
This record conservatively reflects disclosed Phase 1 results. Current Phase 2 initiation and enrollment require confirmation from the original registry.
Once-weekly potential, comparative efficacy, and commercial value require complete clinical results.
